71170-82-6Relevant articles and documents
Palladium-Catalyzed Regioselective C?H Arylation of 4-Azaindazole at C3, C5 and C7 Positions
Faarasse, Soukaina,El Kazzouli, Sa?d,Bourzikat, Otmane,Bourg, Stéphane,Aci-Sèche, Samia,Bonnet, Pascal,Suzenet, Franck,Guillaumet, Gérald
supporting information, p. 3937 - 3945 (2021/03/29)
Direct and site-selective C5 and C7 palladium-catalyzed C?H arylations of 4-azaindazole N-oxide have been achieved. A bidentate ligand and Pd(OAc)2 catalyst in toluene promoted the activation of C5 position, while a phosphine ligand and PdCl2 catalyst in DMA directed the arylation at C7 position. Using this new method, the synthesis of C5, C7-diarylated 4-azaindazole N-oxides as well as the C3, C5, C7-triarylated 4-azaindazoles was achieved towards future medicinal compounds development. (Figure presented.).
PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA
-
Page/Page column 60; 61, (2017/09/02)
Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer,or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.
Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)
Engers, Darren W.,Blobaum, Anna L.,Gogliotti, Rocco D.,Cheung, Yiu-Yin,Salovich, James M.,Garcia-Barrantes, Pedro M.,Daniels, J. Scott,Morrison, Ryan,Jones, Carrie K.,Soars, Matthew G.,Zhuo, Xiaoliang,Hurley, Jeremy,Macor, John E.,Bronson, Joanne J.,Conn, P. Jeffrey,Lindsley, Craig W.,Niswender, Colleen M.,Hopkins, Corey R.
, p. 1192 - 1200 (2016/10/03)
The efficacy of positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclinical rodent models of Parkinson's disease has been established by a number of groups. Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506). We detail the discovery of VU0418506 starting from a common picolinamide core scaffold and evaluation of a number of amide bioisosteres leading to the novel pyrazolo[4,3-b]pyridine head group. VU0418506 has been characterized as a potent and selective mGlu4 PAM with suitable in vivo pharmacokinetic properties in three preclinical safety species.